ALNY News and Press, Alnylam Pharmaceuticals Inc. From 07/21/21

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2021 on Tuesday, August 3, 2021, before the U.S. financial markets open. Management will provide an u...

Arrowhead's stock dropped 25% on preliminary update from ongoing chronic toxicology study in rats causing voluntary pause. However, further safety data released later on could possibly reverse this. While safety issue noted with ARO-ENaC for Cystic Fibrosis, there's another clinical c...

Shares of Alnylam (NASDAQ: ALNY) recently dipped after Intellia (NASDAQ: NTLA) stole the spotlight with trial results for a revolutionary new gene therapy that could compete with Onpattro, Alnylam's top drug at the moment. It does look like Onpattro could be in for some ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’ve never bought a biotech stock before, I don’t blame you. When I made my first-ever biotech bet in my early 20s, things turned out as you might expect: Source: Shutterstock The company declared ...

Alnylam Pharmaceuticals (ALNY) has initiated Phase 2 KARDIA-1 study evaluating the efficacy and safety of zilebesiran for the treatment of hypertension.Zilebesiran will be evaluated as monotherapy across different doses administered quarterly and biannually. The primary endpoint is the change...

– KARDIA-1 will Evaluate Efficacy and Safety of Quarterly and Biannual Regimens of Zilebesiran as Monotherapy – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced initiation of KARDIA-1, a global Phase 2 stu...

Arbutus presented five abstracts at EASL International Liver Congress 2021, one presentation dealing with long-term dosing of AB-729 for Hepatitis B patients was given as a late-breaker oral presentation. 60 mg AB-729 given once every four weeks had achieved a similar HBsAg decline fo...

Alex Potemkin/iStock Unreleased via Getty Images Sensei downgraded, price trimmed on program discontinuation Oppenheimer has downgraded shares of Sensei Biotherapeutics (SNSE) from outperform to perform and has removed its $36 price target in the wake of discontinuing the SNS-301 program for&...

wildpixel/iStock via Getty Images Shares of Alnylam Pharmaceuticals (ALNY) are under pressure today following this past weekend's release of data on a CRISPR gene editing candidate from Intellia (NTLA) for a liver disorder. The interim Phase 1 data on CRISPR candidate NTLA-2001 showed that it...

Greenland Technologies (GTEC) -13% after prices $7.0M underwritten public offering of ordinary shares.Alnylam Pharmaceuticals (ALNY) -10%.Trevena (TRVN) -10% on addition to Russell 2000, Russell 3000, and Russell Microcap Indexes.Atossa Therapeutics (ATOS) -10%.Exelixis (EXEL)&...